Stockreport

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Fortress Biotech, Inc.  (FBIO) 
Last fortress biotech, inc. earnings: 11/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: fortressbiotech.com
PDF Study is the first randomized, controlled trial examining a vaccine’s effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot st [Read more]